PHARMAC proposes listing of Harvoni and Viekira Pak
New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on two proposals to list two new treatments for hepatitis C.
The proposals are as a result of two separate provisional agreements, one with local subsidiary of Gilead Sciences (Nasdaq: GILD) and another with AbbVie (NYSE: ABBV). In summary, the proposals would result in, from July 1, 2016:
- Ledipasvir with sofosbuvir (Harvoni) being funded in the community and District Health Board (DHB) hospitals for the treatment of hepatitis C for patients with severe liver disease.
- Paritaprevir with ritonavir and ombitasvir co-packaged with dasabuvir (Viekira Pak) and paritaprevir with ritonavir and ombitasvir co-packaged with dasabuvir and ribavirin (Viekira Pak-RBV) being funded in the community and DHB hospitals for the treatment of hepatitis C.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze